HC Wainwright Has Positive Forecast for ACRS FY2026 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities researchers at HC Wainwright increased their FY2026 earnings per share estimates for Aclaris Therapeutics in a research report issued on Monday, March 16th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.52) per share for the year, up from their prior estimate of ($0.53). HC Wainwright has a “Buy” rating and a $16.00 price objective on the stock. The consensus estimate for Aclaris Therapeutics’ current full-year earnings is ($0.82) per share.

Other equities analysts have also issued research reports about the stock. Craig Hallum initiated coverage on shares of Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price objective on the stock. Wall Street Zen downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aclaris Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Stock Up 3.7%

Shares of NASDAQ ACRS opened at $3.88 on Wednesday. The firm has a market cap of $467.93 million, a PE ratio of -7.32 and a beta of 0.88. The company’s fifty day simple moving average is $3.35 and its 200 day simple moving average is $2.74. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.The company had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million.

Institutional Trading of Aclaris Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new position in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $37,000. AXQ Capital LP bought a new stake in Aclaris Therapeutics during the third quarter worth $27,000. CIBC Asset Management Inc bought a new stake in Aclaris Therapeutics during the fourth quarter worth $52,000. China Universal Asset Management Co. Ltd. purchased a new stake in Aclaris Therapeutics in the 4th quarter valued at $53,000. Finally, ProShare Advisors LLC purchased a new stake in Aclaris Therapeutics in the 2nd quarter valued at $26,000. 98.34% of the stock is owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.